<DOC>
	<DOCNO>NCT00161928</DOCNO>
	<brief_summary>The primary aim study show NeisVac-C influence seroconversion rate induce hepatitis B ( Hep B ) , inactivate polio ( IPV ) acellular pertussis ( aP ) vaccines infant .</brief_summary>
	<brief_title>Study NeisVac-C Vaccine Evaluate Immunological Interference With Hepatitis B , Inactivated Polio Acellular Pertussis Vaccines Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female volunteer infant , age 2 6 month Clinically healthy , ( i.e . physician would reservations vaccinate meningococcal C vaccine outside scope clinical trial ) Parent ( ) /legal guardian understands study provide write informed consent his/her infant 's study participation Parent ( ) /legal guardian infant available duration study History vaccinerelated contraindicate event ( e.g . anaphylaxis ) Rash dermatological condition injection site could interfere injection site reaction monitor lead dermatological reaction Subjects receive receive vaccine ( ) Â± 30 day study period Concurrent participation previous participation clinical trial investigational medicinal product Subjects suffer disease ( e.g . autoimmune disease ) undergo form treatment ( e.g . systemic corticosteroid , chemotherapeutics ) expect influence immunological function Subjects previously receive vaccination Hep B meningococcal C Subjects receive banked human blood immunoglobulin within one month study entry</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Meningococcal Vaccine</keyword>
	<keyword>Meningococcal Meningitis , Serogroup C</keyword>
	<keyword>Neisseria Meningitidis</keyword>
</DOC>